MYCN and neuroblastoma: Others, like the targeting of the exosome in MYCN‐driven neuroblastoma or CTR9 in PDAC are still to be validated using compounds in vivo, but are still promising targets that promise less toxicity and better drugability than MYC proteins itself [33, 35].